Background Plasma glial fibrillary acidic protein (GFAP) has emerged as a promising
biomarker in neurological disorders, but further evidence is required in relation to its …

Introduction This study examined plasma glial fibrillary acidic protein (GFAP) as a biomarker
of cognitive impairment due to Alzheimer's disease (AD) with and against plasma …

Background Glial fibrillary acidic protein (GFAP) is a promising candidate blood‐based
biomarker for Alzheimer's disease (AD) diagnosis and prognostication. The timing of its …

Introduction There is a tremendous need for identifying reliable blood-based biomarkers for
Alzheimer's disease (AD) that are tied to the biological ATN (amyloid, tau and …

Reliable blood biomarkers for Alzheimer's disease (AD) are missing. We measured
astroglial GFAP in patients with AD (n= 28), frontotemporal dementia (bvFTD, n= 35) …

Glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal protein, can be measured in
blood samples, and has been associated with Alzheimer's disease (AD). However, plasma …

Introduction Plasma glial fibrillary acidic protein (GFAP) is a marker of astroglial activation
and astrocytosis. We assessed the ability of plasma GFAP to detect Alzheimer's disease …

Background: Measuring plasma glial fibrillary acidic protein (GFAP) alongside cortical
amyloid-β (Aβ) may shed light on astrocytic changes in aging and Alzheimer's disease (AD) …

Background: It is still unknown if serum glial fibrillary acidic protein (GFAP) is a useful marker
in frontotemporal lobar degeneration (FTLD). Objective: To assess the diagnostic and …

Introduction: Plasma glial fibrillary acidic protein (GFAP) may be associated with amyloid
burden, neurodegeneration, and stroke but its specificity for Alzheimer's disease (AD) in the …